Current Grant Support
NIH/NIAID/UCSD, (U19 AI070535) “AADCRC RNA Sequencing Core for Airway Epithelial Cells” (2020-2021). Gern, Subaward PI
NIH/NIAID (UM1 AI114271), “The effects of allergen associated type-2 inflammation and particulate matter inflammation in the airway epithelium on SARS-CoV-2 infection” (2020-2021). Gern, Multiple PI
NIH/NHLBI/Rutgers (R56 HL142890), “Mechanisms of Rhinovirus-induced airway hyperresponsiveness: an airway smooth muscle perspective” (2020-2025). Bochkov, Subaward PI
NIH/NIAID (UM2 AI130836), “New Horizons in the prevention and treatment of food allergy – SUNBEAM” (2020-2021). Gern, Subaward PI
NIH/NIAID (U19 AI104317), “Identifying coronavirus B-cell epitopes associated with COVID-19 illness severity” Supplement to “Viral and environmental determinants of rhinovirus illness severity” (2020-2023). Gern, PI
NIH/NIAID (U19 AI104317), “Human Epidemiology and Response to SARS-CoV-2 (HEROS)” Supplement to “Viral and environmental determinants of rhinovirus illness severity” (2013-2023). Gern, PI
NIH/NIAID (R01 AI148707), “Mechanisms of Enhanced Neutralizing Antibody Responses to Rhinovirus C” (2020-2025). Bochkov, PI; Gern, Co-Investigator.
NIH/NIAID/UCSD (U19 AI070535) “Generation of a Mouse Model for RV-C Infection” (2020-2021). Bochkov, Subaward PI
NIH/NIAID (U19 AI142720), “Novel antimicrobials targeting MDR pathogens from animal microbial symbionts” (2019-2024). Gern, Project III Co-Investigator
UW Office of the VCGRE, “The human microbiome in health and disease” (2018 – 2023). Gern, Co-PI
NIH/Office of the Director (UH3 OD023282), “Children’s Respiratory and Environmental Workgroup (CREW)” (2016-2023). Gern, PI
NIH/NIAID (U19 AI104317), “Viral and environmental determinants of rhinovirus illness severity” (2013-2023). Gern, PI
NIH/NIAID (R21 AI144744), “Nasal cytokine responses in children with viral upper respiratory infection” (2019-2021). Gern, Co-Investigator
Wisconsin Partnership Program, “Integrated metabolomics, microbial genomics and immune profiling in early infancy to identify biomarkers for allergic disease prevention” (2018-2021). Gern, Co-Investigator
NIH/NIAID (UM1 AI114271), “Inner City Asthma Consortium (ICAC)” (2002-2021). Gern, Co-PI
Completed Grant Support
Arctic Therapeutics, “Testing RV-C inhibitors and receptor function of animal CDHR3 sequences in HeLa cells” (2018-2019). Bochkov, PI
NIH/NIAID and Boston Children’s Hospital (R01 AI108588), “Viral persistence & the microbiome in bronchiolitis and risk of recurrent wheeze” (2015-2019). Gern, Co-Investigator
NIH/NHLBI (P01 HL070831), “Childhood Origins of ASThma (COAST): rhinovirus infections in children and adolescents” (2002-2019). Gern, Project II Leader
Wisconsin Partnership Program, “Zooming in on childhood asthma: disease causality and personalized medicine” (2015-2018). Gern, Co-Investigator
NIH/NIAID and Massachusetts General Hospital (R01 AI114552), “Infant specific-IgE, rhinovirus-C bronchiolitis, and incident asthma in MARC-35” (2014-2017). Gern, Co-Investigator
NIH/NIAID (T32 AI007635), “Wisconsin allergy and immunology research training program” (2000-2017). Gern, PI
NIH/NIAID (U19 AI104317-04S1), “A first-in-human safety and dose-finding study of new type-16 human rhinovirus (RG-HRV-16) inoculum in healthy volunteers” (2016-2017). Gern, PI
NIH/NIAID (R01 AI097172), “Sinusitis in children: viruses and the nasopharyngeal microbiome” (2011-2016). Gern, Co-Investigator
NIH/NIAID and University of California-San Francisco (P01 AI089473), “Virus/microbe interactions and asthma” (2014-2015). Gern, Co-Investigator
NIFA/USDA, “Preventing food protein allergic reactions via conjugation with polysaccharides” (2011-2015). Gern, Co-Investigator
Schering-Plough Corporation, “Selective induction of pro-inflammatory mediators in asthmatic subjects following experimental infection with HRV-16” (2012-2013). Gern, PI
NIH/NIAID (U19 AI070503), “Mechanisms of rhinovirus-induced exacerbations of asthma” (2006-2013). Gern, PI
AstraZeneca, “The effect of ‘adjustable’ treatment with budesonide/formoterol on rhinovirus provoked exacerbations of asthma D-Code-D589BN00028-P” (2008-2011). Gern, PI
NIH/NIAID and University of Virginia (U19 AI070364), “Using the experimental virus challenge model to decipher the asthmatic response to rhinovirus” (2008-2010). Gern, Co-Investigator
NIH/NIAID (R01 HL080072), “T regulatory cells and childhood asthma” (2004-2010). Gern, PI
NIH/NIAID and Baylor College of Medicine (U19 AI070412), “Rhinoviral proteinases in experimental asthma: development of a method for preparation of LPS-free rhinoviral proteases” (2009). Gern, Co-Investigator
NIH/NHLBI (R01 HL080412), “Viral Induced Asthma Exacerbations (VIAX)” (2005-2009). Gern, Co-Investigator
NIH/NIAID (U19 AI070503, supplement), “Plasmid-based HRV-16 human inoculum” (2007-2008). Gern, PI
NIH and University of Texas-San Antonio, “Reverse genetic approach to produce type-16 rhinovirus in GMF facility: mechanisms of rhinovirus-induced exacerbations of asthma” (2007-2008). Gern, Co-Investigator
Merck, Inc, “Effect of montelukast on experimentally-induced RV16 infection in volunteers with mild asthma” (2005-2008). Gern, PI
Proctor & Gamble Company, “Common cold research” (2000-2008). Gern, PI
NIH/NCRR (M01 RR003186) “General clinical research center” (2005-2007). Gern, Assistant Director for Pediatrics and
Medical Education for the University of Wisconsin-Madison GCRC
GlaxoSmithKline, “Inoculation of volunteers with a new safety tested inoculum of type-16 human rhinovirus” (2004-2007). Gern, PI.
NIH/NIAID (P01 AI050500), “Mechanisms of virus-induced asthma” (2001-2007). Gern, PI
NIH/NIMH (R01 MD066073), “Anxiety & inflammatory correlates in youth with eczema” (2004-2006). Gern, Co-Investigator
Aguoron Pharmaceuticals, Inc., “A phase II, randomized, placebo-controlled, double-blind, multicenter study of ruprintrivir (ag7088) nasal spray, 0.2% solution for the treatment of natural rhinovirus infection in adults A433-1001” (2002-2005). Gern, PI.
Perlan Therapeutics, Inc., “Pre-clinical studies” (2001). Gern, PI